BeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says

MT Newswires Live06-02

BeOne Medicines (ONC) reported encouraging data from three solid tumor programs, strengthening confidence in its competitive potential and long-term growth, RBC Capital Markets said in a note Tuesday.

The company on Monday presented "promising" data on a CDK4 inhibitor for breast cancer, a GPC3-4-1BB bispecific antibody for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer.

Analyst Leonid Timashev said each therapy appears to be delivering on its promised profile, with potential safety or efficacy advantages that could support best-in-class positioning or at least strong competitiveness over the coming years.

Although investors have generally been skeptical of BeOne Medicines' solid tumor portfolio, RBC believes the building blocks for success are becoming increasingly visible. As a result, the firm now estimates that the company could generate up to $4.8 billion in solid tumor sales by 2035.

"While more data, and in some cases, optimization is still needed, we think the company's commitment to phase 3 trials and initial data is worth paying attention to," the analyst added.

RBC raised its price target on BeOne Medicines to $436 from $425 while keeping its outperform rating.

Price: 276.76, Change: -2.92, Percent Change: -1.04

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640463941?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 23:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640463941","market":"sh","top_or_hot":-1,"title":"BeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says","media":"MT Newswires Live","content":"<html><body><p> BeOne Medicines (ONC) reported encouraging data from three solid tumor programs, strengthening confidence in its competitive potential and long-term growth, RBC Capital Markets said in a note Tuesday.</p><p>The company on Monday presented \"promising\" data on a CDK4 inhibitor for breast cancer, a GPC3-4-1BB bispecific antibody for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer.</p><p>Analyst Leonid Timashev said each therapy appears to be delivering on its promised profile, with potential safety or efficacy advantages that could support best-in-class positioning or at least strong competitiveness over the coming years.</p><p>Although investors have generally been skeptical of BeOne Medicines' solid tumor portfolio, RBC believes the building blocks for success are becoming increasingly visible. As a result, the firm now estimates that the company could generate up to $4.8 billion in solid tumor sales by 2035.</p><p>\"While more data, and in some cases, optimization is still needed, we think the company's commitment to phase 3 trials and initial data is worth paying attention to,\" the analyst added.</p><p>RBC raised its price target on BeOne Medicines to $436 from $425 while keeping its outperform rating.</p><p>Price: 276.76, Change: -2.92, Percent Change: -1.04</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-02 23:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BeOne Medicines (ONC) reported encouraging data from three solid tumor programs, strengthening confidence in its competitive potential and long-term growth, RBC Capital Markets said in a note Tuesday.</p><p>The company on Monday presented \"promising\" data on a CDK4 inhibitor for breast cancer, a GPC3-4-1BB bispecific antibody for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer.</p><p>Analyst Leonid Timashev said each therapy appears to be delivering on its promised profile, with potential safety or efficacy advantages that could support best-in-class positioning or at least strong competitiveness over the coming years.</p><p>Although investors have generally been skeptical of BeOne Medicines' solid tumor portfolio, RBC believes the building blocks for success are becoming increasingly visible. As a result, the firm now estimates that the company could generate up to $4.8 billion in solid tumor sales by 2035.</p><p>\"While more data, and in some cases, optimization is still needed, we think the company's commitment to phase 3 trials and initial data is worth paying attention to,\" the analyst added.</p><p>RBC raised its price target on BeOne Medicines to $436 from $425 while keeping its outperform rating.</p><p>Price: 276.76, Change: -2.92, Percent Change: -1.04</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDCO","symbol_name":"麦迪逊医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640463941","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640463941","pubTimestamp":1780412648,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BeOne Medicines  reported encouraging data from three solid tumor programs, strengthening confidence in its competitive potential and long-term growth, RBC Capital Markets said in a note Tuesday.The company on Monday presented \"promising\" data on a CDK4 inhibitor for breast cancer, a GPC3-4-1BB bispecific antibody for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer.Analyst Leonid Timashev said each therapy appears to be delivering on its promised profile, with potential safety or efficacy advantages that could support best-in-class positioning or at least strong competitiveness over the coming years.Although investors have generally been skeptical of BeOne Medicines' solid tumor portfolio, RBC believes the building blocks for success are becoming increasingly visible. As a result, the firm now estimates that the company could generate up to $4.8 billion in solid tumor sales by 2035.\"While more data, and in some cases, optimization is still needed, we th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDCO":"麦迪逊医药","ONC":"百济神州","BK4588":"碎股","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"加拿大皇家银行表示，BeOne Medicines实体瘤数据增强了对长期增长的信心","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1,"MDCO":1.5},"content_text":"BeOne Medicines (ONC) reported encouraging data from three solid tumor programs, strengthening confidence in its competitive potential and long-term growth, RBC Capital Markets said in a note Tuesday.The company on Monday presented \"promising\" data on a CDK4 inhibitor for breast cancer, a GPC3-4-1BB bispecific antibody for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer.Analyst Leonid Timashev said each therapy appears to be delivering on its promised profile, with potential safety or efficacy advantages that could support best-in-class positioning or at least strong competitiveness over the coming years.Although investors have generally been skeptical of BeOne Medicines' solid tumor portfolio, RBC believes the building blocks for success are becoming increasingly visible. As a result, the firm now estimates that the company could generate up to $4.8 billion in solid tumor sales by 2035.\"While more data, and in some cases, optimization is still needed, we think the company's commitment to phase 3 trials and initial data is worth paying attention to,\" the analyst added.RBC raised its price target on BeOne Medicines to $436 from $425 while keeping its outperform rating.Price: 276.76, Change: -2.92, Percent Change: -1.04","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640463941","isCrawlerRequest":true}